Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

Trial Details

NCT ID
NCT07216248
Phase
PHASE2
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • relugolix + ARPI
  • Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI
  • relugolix or androgen deprivation therapy (ADT) + ARPI
  • relugolix + ARPI.
Locations (sample)
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Cohort A Eligibility (Step 1 Registration)
  • Participant aged ≥ 18 years
  • Hormone-sensitive prostate cancer with histologically/cytologically confirmed adenocarcinoma without small cell histology.
  • Metastasis detected any time prior to study registration on conventional or functional imaging as determined by the treating investigator and can b…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →